posted by mike kraft
on Tue, 2024-10-08 10:48
GSK RSV vaccine is still 43% effective against severe disease after third year
GSK RSV shot 43% effective against severe disease in third yearhttps://
Oct 8 (Reuters) - GSK (GSK.L) said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in its third season after patients received the shot.
That compares with 94.1% effectiveness in preventing severe RSV in the first season and 64.2% a year later, according to data from GSK's Phase 3 clinical trial. The trial initially enrolled about 25,000 volunteers in 17 countries.
...
Country / Region Tags:
General Topic Tags:
Problem, Solution, SitRep, or ?:
Groups this Group Post belongs to:
- Private group -
